We're eager to share insights and learn from health system leaders at #HLTHUSA 2024 in Las Vegas, Oct. 20-23. Kevin Torres and Patra Glavin, Key Account Partnerships Executives, look forward to meeting with healthcare systems and employer groups interested in leveraging our FirstLook Test for lung cancer to enhance screening among their eligible patients and members. Reach out to Kevin or Patra to schedule a time to connect. Come visit us at Meeting Pod #6458 to learn more about DELFI, the FirstLook Lung test and our DELFI-Tumor Fraction research service. Our CEO, Susan Tousi will make an exciting announcement from the Newsroom Stage on Tuesday, October 22 at 3:00 PM PST. You won’t want to miss it! We hope to see you there!
DELFI Diagnostics
生物技术研究
Baltimore，Maryland 15,376 位关注者
Saving lives through early cancer detection
关于我们
DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
- 网站
-
https://www.delfidiagnostics.com
DELFI Diagnostics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Baltimore，Maryland
- 类型
- 私人持股
- 创立
- 2019
地点
-
主要
获取路线
2809 Boston St
Suite 503
US，Maryland，Baltimore，21224
DELFI Diagnostics员工
动态
-
We are honored that #DELFI has been featured in Johns Hopkins Technology Ventures (JHTV) “10 Innovations in 10 Years” series, which recognizes the achievements of our founders Victor Velculescu and Robert Scharpf along with the entire DELFI Diagnostics team.
Over the next few months, we’ll spotlight a decade of groundbreaking innovations at Johns Hopkins University. Next up: DELFI Diagnostics’ next-gen liquid biopsy tests, developed by Victor Velculescu and Robert Scharpf at the Johns Hopkins Kimmel Cancer Center, revolutionizing early cancer detection. DELFI stands for “DNA evaluation of fragments for early interception.” When cells die, they release fragments of DNA into the bloodstream, called cell-free DNA or cfDNA. Investigators have found that the packaging of these fragments is different in cancer patients than in healthy individuals. Learn more about DELFI and their progress in developing affordable blood tests to improve early lung cancer detection. https://lnkd.in/enYRBNw9
-
-
#DELFI is thrilled to announce that Allyson Perdue, Key Account Partnerships Executive, will attend the D.C. Lung Cancer Conference 2024 on October 19. Please visit our booth to learn more about our blood-based FirstLook Test for lung cancer screening! This one-day multidisciplinary conference will provide a comprehensive update on recent clinical advances in #lungcancer including CT screening, liquid biopsies, and interpretation of molecular testing results. You can find more information here: https://lnkd.in/eT2pi6xh #earlydetection #cancerdetection @IASLC
-
-
#DELFI is proud to honor #IndigenousPeoplesDay today. We are taking time today to acknowledge the history, celebrate the rich diversity, and better understand how we can improve lung cancer screening in Indigenous communities. Our partner, Indigenous Pact PBC, Inc., is a leader in advocating for healthcare equity for Tribal communities and was recently recognized by The White House #BidenCancerMoonshot. Learn more about Indigenous Pact here: https://lnkd.in/ewEis5ni #IndigenousPeoplesDay
-
Stop by our FirstLook Test booth today at the 6th Annual Jefferson Health Lung Cancer Screening Summit in Philadelphia at Thomas Jefferson University. Nicole Trieste Otto, MBA, RN, Associate Director of Clinical Implementation, and Allyson Perdue, Key Account Partnerships Executive, are excited to share #DELFI’s efforts to enhance lung cancer screening for eligible patients with our innovative blood test. #earlydetection #cancerdetection #jeffersonhealth #thomasjeffersonuniversity
-
-
Today is the day! #DELFI's Senior Medical Director Dr. Lindsey C. presents a poster at #CHEST2024 in Boston at 10:20 AM. The annual CHEST conference gathers key stakeholders in the pulmonary health space. Dr. Cotton's poster, titled "Improving the Efficiency of Lung Cancer Screening Through the Use of a Point-of-Care, Blood-Based Lung Cancer Screening Test Prior to Low-Dose CT Scan," will be presented from 10:20am - 11:05am ET. Poster #4184. Please see details here: https://bit.ly/3MQqPV4 #lungcancer #screening #prevention
-
-
Congratulations, Dr. Victor Velculescu, on this well-deserved award and distinction!
Co-founder & President, PMWC Intl / 33,000 LI Followers / PMWC Newsletters 92,000+ subscribers since 2009
Honoring Dr. Victor Velculescu at PMWC 2025 + Insights from His Groundbreaking Work in Cancer Detection We’re thrilled to announce that Dr. Victor Velculescu, a leader in cancer genomics and liquid biopsy technologies, will be awarded the Pioneer Award at PMWC 2025 on February 6th during the Clinical Utility of Liquid Biopsies track. He will also deliver a keynote on “Early Detection of Cancer Using Cell-free DNA Fragmentomes,” sharing insights on how DELFI (DNA Evaluation of Fragments for Early Interception), his AI-driven liquid biopsy platform by DELFI Diagnostics, is revolutionizing early cancer detection and chair a session on Innovative Approaches in Liquid Biopsy. Interview Highlights: DELFI: A Breakthrough Technology Analyzes cell-free DNA fragmentomics with AI to detect early-stage cancers, making screening more accessible and affordable. Personalized Cancer Treatments Velculescu’s research on genes like PIK3CA drives targeted therapies matched to patients' unique tumor profiles. Addressing Global Disparities DELFI is scalable and cost-effective, aiming to broaden access to cancer screening in diverse healthcare settings. Other Key Sessions at PMWC 2025 on February 6th: ?? Pioneer Honoree: Victor Velculescu, Johns Hopkins and DELFI Diagnostics ?? Luminary Honoree: Nicola Aceto, ETH Zurich ?? Keynote: Circulating Tumor Cells, Nicola Aceto, ETH Zurich ?? Panel: Innovative Approaches in Liquid Biopsy, chaired by Victor Velculescu, featuring Adam Widman (MSKCC) ?? Panel: Circulating Tumor Cells: The New Frontier, chaired by Nicola Aceto, ETH Zurich ?? Panel: Multi-Cancer Early Detection, featuring Joshua Cohen (Haystack), Josh Ofman (Grail Bio), and Lauren Leiman (BLOODPAC). See the full PMWC 2025 program here: https://lnkd.in/gPtkWZbQ For the full interview with Dr. Velculescu: https://lnkd.in/gXBjRY9D #PrecisionMedicine #LiquidBiopsy #CancerDetection #AIinHealthcare #PersonalizedMedicine #HealthcareInnovation #PMWC2025 Join us in congratulating him: DELFI Diagnostics, Andrea Califano Tomasetti Alex Sockell, PhD Luis Diaz Hetty Carraway Rob Genuario Yardena Samuels Manu Kohli Naomi Thomson Todd Krueger Rami Zahr Phillip Buckhaults Susan Tousi Justin Klein, MD, JD Blandine Merino Sam Raha Timothy McDaniel William Stevens Jason Sagert Saraswati Sukumar Desmond Opare Agyekum, MBA,MPH (he/him) Navonil De Sarkar Marija Debeljak Jin JenTobias Sj?blom Hari Easwaran Julie Meyer Scott Gotshall Kurtis Bachman Jennifer Dickey Maureen Collins Pelletier Surajit Dhara ,Paula Vertino Sam Thiagalingam Mary T. Padilla, M.D. Morassa Mohseni, PhD John Dierkes Jiuxiang(Julie) Zhu.
-
-
#DELFI is gearing up for the 6th Annual Jefferson Health #LungCancerScreening Summit on October 10 in Philadelphia. The event, hosted by Thomas Jefferson University, aims to review the latest knowledge and research, convening a multidisciplinary group inclusive of physicians, nurses, program coordinators, researchers, and other experts focused on #earlydetection of #lungcancer. #DELFI's Nicole Trieste Otto, MBA, RN, Associate Director of Clinical Implementation, and Allyson Perdue, Key Account Partnerships Executive will attend the summit on October 10 in Philadelphia. Stop by the FirstLook Test booth to connect with them! #earlydetection #cancerdetection #jeffersonhealth #thomasjeffersonuniversity
-
-
Allegheny Health Network (AHN) and #DELFI announce a collaboration to evaluate the effectiveness of DELFI’s FirstLook Test’s ability to enhance #lungcancerscreening rates in western Pennsylvania. The FirstLook Lung blood test will be available from AHN’s pulmonary and primary care practices where eligible patients will submit a blood sample. The sample will be sent to our clinical laboratory where our whole-genome machine learning platform will analyze fragments of cell-free DNA to identify patterns associated with the presence of lung cancer. Ali Zaidi, MD, Medical Director of Aerodigestive Research at AHN, says, “The FirstLook blood test may help us better identify those who are most at risk of this disease and who would benefit from follow-up CT screening.” Click here to read more about this exciting collaboration: https://bit.ly/4dAURqU
-
-
And that's a wrap! #DELFI would like to give a warm thank you to the organizers of the GO2 for Lung Cancer Centers for Excellence Summit / Lung #Cancer Navigator Workshop in Chicago for a thought-provoking conference for #lungcancer professionals. Our attendees, Account Executives Allyson Perdue and Kevin Torres are returning inspired to change the healthcare paradigm. #DELFI is proud to have supported the event, and we look forward to next year's conference!
-